Latest from Actorius

Oct 17, 2025

Circulating Biomarkers Reveal their Complementary Association in Primary and Metastatic Colorectal Cancer Patients

Combined CTC and ctDNA analysis reveals strong prognostic value for monitoring progression and metastasis in colorectal cancer patients.

Oct 17, 2025

ESMO 2025 | 17–21 October 2025

Actorius at ESMO 2025

Sep 16, 2025

PD-L1 overexpression on circulating tumor cells and CTC clusters: A potential biomarker across solid carcinomas

Correlation of CTC detection, PD-L1 expression, and CTC clusters highlights biomarkers for minimal residual disease and cancer progression monitoring.

Sep 16, 2025

Profiling of PD-L1 and HER2 over expression on cancer cells using AI based macro-driven automation

AI-based image analysis rapidly profiles circulating tumor cells, quantifying morphology and biomarkers like PD-L1 and HER2 for cancer research.

Jun 3, 2025

PD-L1 expression on circulating tumor cells and CTC clusters as a minimal cellular disease in breast cancer patients.

This breast cancer study shows high prevalence of PD-L1–positive circulating tumor cells, supporting their role in minimal residual disease and metastasis risk.

Jun 3, 2025

Circulating tumor cells and clusters exhibiting expression of PD-L1 in colorectal patients.

High prevalence of PD-L1–positive circulating tumor cells in colorectal cancer highlights their role in minimal residual disease and recurrence monitoring.

Jun 3, 2025

Use of dynamic blood flow device with conjugated affinity ligands on glass substrate to capture circulating tumor cells in cancer patients.

Continuous-flow 3D glass substrate device safely captures circulating tumor cells, demonstrating potential to reduce metastasis and improve cancer survival.

Jun 3, 2025

Quadrant of co-occurrence of circulating tumor DNA and PD-L1 expression on circulating tumor cells in monitoring disease aggressiveness and metastasis in lung cancer.

Combined ctDNA and PD-L1–positive CTC analysis improves monitoring of metastasis, minimal residual disease, and treatment response in lung cancer.

Jun 3, 2025

Comparative analysis of circulating tumor cell distribution with PD-L1 expression in baseline and follow ups patients across cancer types.

This multi-cancer study shows CTC and PD-L1 prevalence across Indian patients, supporting minimal residual disease monitoring and personalized cancer care.

May 9, 2025

Accounts of circulating tumor cells and CTC clusters with PD-L1 expression in sarcoma patients

Study shows circulating tumor cells with PD-L1 expression and clusters in sarcoma, indicating minimal residual disease and need for long-term monitoring.

May 9, 2025

ISMRC 2025 | 7-9 May, 2025

Actorius at ISMRC 2025

Mar 14, 2025

Manuscript: The impact of co-occurring tumor suppressor mutations with mEGFR as early indicators of relapse in lung cancer

A set of 17 co-occurring TSG mutations has been identified as key biomarkers for early relapse in mEGFR
lung adenocarcinoma. Longitudinal genomic monitoring, with a focus on clonal evolution, offers valuable insights that can inform personalized treatment strategies and potentially improve patient outcomes.

Nov 25, 2024

ISLB 2024: Transit of Circulating Tumor Cells (CTC) Post Radiotherapy at Irradiated Tumor Regions in Pan-cancer Patients

Study links radiotherapy exposure with circulating tumor cells and PD-L1 expression, indicating possible minimal residual disease and metastatic risk.

Nov 25, 2024

ISLB 2024: Comprehensive Analysis of ctDNA and CTCs Reveals Resistance signatures and Correlations with PET Scan Outcomes in Cancer Patients

Integrated ctDNA and CTC analysis correlates with PET-CT outcomes to reveal treatment resistance and aggressive cancer progression.

Nov 25, 2024

ISLB 2024: Expression of Programmed Death - Ligand 1 as a dynamic biomarker on circulating tumor cells in pancreatic cancer patients

CTC detection with PD-L1 overexpression reveals aggressive pancreatic cancer and potential biomarker value for monitoring metastasis and disease progression.

Sep 17, 2024

ESMO 2024: True single-circulating tumor cell genomics reveals enriched therapy-resistance signatures in advanced colorectal cancer patients

Single CTC genomics reveals actionable mutations and therapy resistance signatures not detected in paired ctDNA in advanced colorectal cancer.

Jul 15, 2024

Manuscript: Inverse 3D ‘lab-on-a-chip’ polymeric microfilms for selective capture of circulating tumor cells from patients' blood

Inverse 3D lab-on-chip microfilms for selective CTC capture from blood.

Jun 29, 2024

Manuscript: Circulating Tumor Cells as Biomarkers for Relapse Detection in Rectal Cancer with Liver Metastasis: Insights from a Case Report

In this case report we demonstrate the utility of CTC as a sensitive marker to detect MRD. CTCs play a crucial role in the context of MRD in colorectal cancer, offering a valuable biomarker for prognosis, treatment monitoring, and early detection of recurrence.

Jun 4, 2024

ASCO 2024: Effect of circulating tumor cells in clinically stable patients on the conundrum of recurrence with cellular residual disease.

CTC detection with PD-L1 expression reveals residual disease despite negative radiological findings in treated cancer patients.

Jun 3, 2024

ASCO 2024: Effect of circulating tumor cells (CTC) and CTC clusters with PD-L1 dynamic biomarker on cellular burden in patients with ovarian cancer.

CTCs with PD-L1 expression in ovarian cancer reveal minimal residual disease and may guide immunotherapy and early metastasis monitoring.

Jun 3, 2024

ASCO 2024: Measure of minimal residual burden on CTCs with over-expression of PD-L1 as a dynamic biomarker in patients with colorectal cancer.

CTC detection with PD-L1 expression in colorectal cancer reveals minimal residual disease and supports personalized treatment strategies.

Jun 3, 2024

ASCO 2024: Impact of ctDNA genomic mutations and CTCs biomarker duo on clinical concordance in localized, progressive, and metastatic disease.

Dual biomarker analysis of ctDNA and circulating tumor cells reveals disease progression and metastasis across multiple cancer types.

Jun 3, 2024

ASCO 2024: Association of complementing ctDNA and CTCs load on stable and progressive disease in treated patients.

Complementary ctDNA and CTC biomarkers reveal minimal residual disease and predict cancer progression after curative-intent treatment.

Apr 11, 2024

Magnetic nanocrystals capture tumour cells from blood samples

These nanomaterials could speed up discovery of anti-cancer drugs

Apr 10, 2024

AACR 2024: Distribution prophecy of circulating tumor cell clusters in CTC populace patients of epithelial cancers

Large-scale analysis of circulating tumor cells and clusters reveals their role in predicting aggressive epithelial cancers and treatment resistance.

Apr 10, 2024

AACR 2024: Evaluation of HER-2 expression on circulating tumor cells as a real time biomarker in advanced breast cancer

HER2 analysis on circulating tumor cells using the OncoDiscover® platform enables real-time, non-invasive profiling for improved metastatic breast cancer treatment decisions.

Apr 4, 2024

Manuscript: CTC together with Shh and Nrf2 are prospective diagnostic markers for HNSCC

Study links Shh/Nrf2 overexpression with circulating tumor cells in HNSCC, highlighting their potential as biomarkers for early detection and survival prediction.

Oct 24, 2023

ESMO 2023: Expression of PD-L1 and EGFR on circulating tumor cells in advanced Lung cancer patients

CTC analysis using OncoDiscover® enables dynamic detection of PD-L1 and EGFR targets in advanced lung cancer, supporting personalized targeted and immunotherapy decisions.

Sep 20, 2023

Manuscript: Magnetically-activated, nanostructured cellulose for efficient capture of CTCs from the blood sample of head and neck cancer patients

Study compares CNC and CNF cellulose nanostructures for EpCAM-based CTC capture in head and neck cancer, enabling affordable real-time cancer monitoring.

Jul 20, 2023

Manuscript: Role of circulating tumour cells (CTCs) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)

This study highlights the utility of CTCs as a disease progression monitoring tool in recurrent HNSCC patients. Our findings suggest the potential clinical utility of CTCs and the need for further exploration in upfront settings of the disease as well (NCT: CTRL/2020/02/023378).